|
|
|
| Changes of Inflammatory Factors and Renal Function with Febuxostat Treatment in Male Patients of Gout Complicated with Hyperuricemia |
| LI Yong-gang |
| Department of Nephrology, Lianshui People's Hospital, Heilongjiang, 223400 |
|
|
|
|
Abstract 【Objective】To explore the changes of inflammatory factors, renal function and febuxostat treatment in male patients with gout and hyperuricemia (HUA). 【Methods】A total of 90 patients with hyperuricemia who were diagnosed and met the criteria in our hospital were selected from April. 2017 to May. 2018. According to the presence of gout, patients were divided into the gout group(n=45) and the non-gout group(n=45). Meanwhile, a total of 45 healthy volunteers who had physical examinations at the same time period were selected as the healthy control group. The changes of inflammatory factors [Hypersensitivity reaction protein (hs-CRP), Interleukin-6 (IL-6)] and renal function [Blood urea nitrogen (BUN), Serum creatinine (SCr), Blood uric acid (SUA), Glomerular filtration rate(eGFR)] were compared among the three groups. The gout group was treated with febuxostat, and the changes of inflammatory factors and renal function were compared before and after three month treatment. 【Results】Levels of hs-CRP, IL-6, SCr, SUA, and eGFR showed statistically significant difference among three groups(P<0.05). However, there were no significant differences in BUN level(P>0.05). Significant differences in SCr, SUA, and eGFR were shown between the gout group and the control group(P<0.05)and there was significant difference of SUA level between the non-gout group and healthy control group(P<0.05). After treatment, the serum levels of hs-CRP, IL-6 and SUA in the gout group were significantly lower than those before treatment and the differences were statistically significant(P<0.05). However,the changes of BUN, SCr and eGFR were not significantly different (P>0.05). 【Conclusion】The serum levels of hs-CRP, IL-6, SCr, SUA,and eGFR were significantly increased in male patients with gout complicated with hyperuricemia. The application of febuxostat can reduce the level of SUA. The clinical efficacy was satisfactory and it is worthy of clinical promotion.
|
|
Received: 16 October 2018
|
|
|
|
|
|
[1] 方迎昕. 高尿酸血症[J].中国实用乡村医生杂志, 2018,(2):9-10.
[2] 王靖宇,常宝成. 高尿酸血症/痛风流行病学特点及危险因素[J].国家内分泌代谢杂志, 2016,36(2):78-81.
[3] 况劲松.痛风和高尿酸血症[J].中国使用乡村医生杂志,2015,22(12):41.
[4] 唐羽裳,刘宏,刘必成.高尿酸血症流行病学数据的变迁及反思[J].药品评价, 2015, 12(7):8-13.
[5] 张彩香,林章梅,梁艳玲,等. 高尿酸血症患者血清白介素-6和转化生长因子-β1水平及应用非布司他治疗前后的变化[J].中国糖尿病杂志,2016,24(3):250-253.
[6] 陈芳,李素梅. 高尿酸血症对肾脏损害的研究进展[J].临床与病理杂志,2016,36(3):285-289.
[7] 涂彩霞,刘旭,李玲,等.痛风治疗新药研究进展[J].国际药学研究杂,2016,43(5):858-861.
[8] 鄢海波,马宁,崔春丽,等. 非布司他治疗痛风性关节炎的疗效及其安全性评价[J].吉林大学学报(医学版),2017,43(1):135-140+216-217.
[9] 农桂敏,黄鹏. 非布司他治疗痛风的临床效果及安全性分析[J].临床合理用药杂志,2018,11(1):38-39.
[10] 陈松,黄键,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472-474.
[11] 杨婷.非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析[J].中国临床药理学杂志,2015,31(184):122-124.
[12] 黄新忠,薛海燕,袁莉.非布司他对慢性肾脏病3~5期合并高尿酸血症患者的肾脏保护作用及相关机制[J].中国现代医学杂志,2017,27(26):97-101. |
|
|
|
2018, Vol. 35 
